The genetics research space has garnered considerable attention from investors in recent years and if you are currently looking for a stock to bet on, then it could be a good idea to have a closer look at the Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTX) stock.
Over the course of the past week or so, the stock has been one of the better performers and managed to record gains of as much as 41%. Brooklyn ImmunoTherapeutics is primarily involved in the development of treatments that are meant for those suffering from rare disease and cancers.
At this point in time, the company’s lead program consists of the development of the product IRX-2. The product is a cytokine therapy that has been derived from human cells and is meant for the treatment of head and neck cancer.
Expert believe that the premise of the product is quite promising but it is not until the first half of next year that the company is going to be able to publish its final results. Up until then, the stock is likely going to be on the radars of many investors who are interested in this particular sector. Investors could add the stock to their watch lists at this point.
Market Reaction:
As of 12:09, BTX stock soared 19% to $22.70 with more than 6.75 million shares, compared to its average volume of 8.20 million shares. The stock has moved within a range of $19.71 – 23.34 after opening the trade at $20. Over the past 52-week, the stock has been trading within a range of $3.04 – 80.67.
 Stock Rockets 40% in a Week: Time To Buy Now?){kind=link}